CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Rating of “Moderate Buy” by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $9.5625.

A number of equities research analysts recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a research report on Friday, August 14th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Finally, Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th.

Insiders Place Their Bets

In related news, CFO Kelly Gold purchased 10,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was purchased at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard A. Young purchased 16,378 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director directly owned 186,388 shares of the company’s stock, valued at $307,540.20. This trade represents a 9.63% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. Insiders own 21.69% of the company’s stock.

Institutional Investors Weigh In On CAMP4 Therapeutics

Several hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC purchased a new position in shares of CAMP4 Therapeutics during the second quarter valued at $27,581,000. 5AM Venture Management LLC purchased a new stake in CAMP4 Therapeutics in the second quarter worth about $25,647,928. Vivo Capital LLC purchased a new stake in CAMP4 Therapeutics in the third quarter worth about $11,765,000. Balyasny Asset Management L.P. bought a new position in CAMP4 Therapeutics during the 4th quarter worth about $14,938,000. Finally, Trails Edge Capital Partners LP bought a new position in CAMP4 Therapeutics during the 2nd quarter worth about $8,446,935.

CAMP4 Therapeutics Price Performance

CAMP4 Therapeutics stock opened at $4.41 on Friday. CAMP4 Therapeutics has a 1-year low of $1.46 and a 1-year high of $7.75. The firm has a market capitalization of $276.73 million, a P/E ratio of -1.90 and a beta of 0.27. The company’s 50-day moving average is $4.13 and its 200 day moving average is $4.35.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Research analysts anticipate that CAMP4 Therapeutics will post -0.57 earnings per share for the current fiscal year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.